drugset / Trial / NCT03844412

Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments

NCT03844412

RandomizedFactorialQuadruple-blindTreatment

Summary

Vestibulodynia (VBD) is a complex chronic vulvar pain condition that impairs the psychological, physical, and sexual health of 1 in 6 reproductive aged women in the United States. Here, the investigators plan to conduct a randomized, double-blinded, placebo-controlled clinical trial to 1) compare the efficacy of peripheral (lidocaine/estradiol cream), centrally-targeted (nortriptyline), and combined treatments in alleviating pain and improving patient-reported outcomes and 2) determine cytokine and microRNA biomarkers that predict treatment response in women with distinct VBD subtypes. Positive findings from this study will readily translate to improved patient care, permitting the millions of women with VBD, their partners, and their clinicians to make more informed decisions about pain management.

Timeline

Start
2019-11-04
Primary completion
2024-03-13
Completion
2024-05-30

Drugs

EvaluationDrugModalityDoseRoute
Comparator Estradiol Other / unclassified 0.02 % Topical
Comparator Estradiol Other / unclassified 5 mg/ml Topical
Comparator Lidocaine Other / unclassified 5 % Topical
Comparator Nortriptyline Small molecule 50 mg Oral